Mechanisms of Electroconvulsive Therapy to Improve Depressive Symptoms and Sleep Regulation Based on the Microbial Gut-brain Axis

Baseline Characteristics for INFRONT-3: A Phase 3 Double-Blind, Placebo-Controlled 96-Week Study Evaluating Latozinemab in FTD-GRN